RenovoRx Inc (NAS:RNXT)

Q3 2025 RenovoRx Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $0.9744 (-2.56%)

Transcript 8-K10-Q

Key Points

Positve

RenovoRx Inc (RNXT) has introduced a new therapeutic option, TAAP, for cancer treatment, which is gaining adoption in academic medical centers and large community hospitals.
The company has achieved year-to-date revenue of approximately $900,000, indicating strong commercial momentum for their Renovocap device.
RenovoRx Inc (RNXT) has expanded from 5 to 14 cancer centers approved to purchase Renovocap, with 5 centers making repeat orders, demonstrating demand and customer satisfaction.
The company has a robust pipeline with 24 centers requesting quotes for Renovocap, and they are engaging with physicians at medical conferences to drive further interest.
RenovoRx Inc (RNXT) has over $10 million in cash and cash equivalents, providing a solid financial foundation to fund ongoing commercialization and clinical trials into mid-2026.

Negative

The company is still in the early stages of commercialization, with relatively minor fluctuations in sales due to limited staff and new market entry.
Research and development expenses were $1.7 million, reflecting ongoing investment needs for clinical trials and studies.
The sales cycle for hospital approvals can be lengthy, ranging from several weeks to several months, which may delay revenue realization.
RenovoRx Inc (RNXT) is focusing solely on the US market for now, potentially missing out on international opportunities.
The company anticipates final enrollment for their Phase 3 Tiger Pack trial only by early 2026, with final data not expected until 2027, indicating a long timeline before potential market expansion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RNXT.OQ - RenovoRx Inc
Q3 2025 RenovoRx Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. I will be your conference call operator today.

Please note that today's call is being recorded and all participants, other than management are in listen-only mode.

There will be a Q&A session following the management's presentation.

I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications. Please go ahead.

Thank you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon everyone and welcome to Renovax's 3rd quarter 2025 conference call.

I'm joined today by

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.